EUVIMEDEUVIMED entdecken
Open Access

Modeling the transmission mitigation impact of testing for infectious diseases

Casey Middleton iD, Daniel B Larremore iD

Science Advances · 2024

DOI: 10.1126/sciadv.adk5108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Casey Middleton und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Science, University of Colorado Boulder, Boulder, CO, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A fundamental question of any program focused on the testing and timely diagnosis of a communicable disease is its effectiveness in reducing transmission. Here, we introduce testing effectiveness (TE)—the fraction by which testing and post-diagnosis isolation reduce transmission at the population scale—and a model that incorporates test specifications and usage, within-host pathogen dynamics, and human behaviors to estimate TE. Using TE to guide recommendations, we show that today’s rapid diagnostics should be used immediately upon symptom onset to control influenza A and respiratory syncytial virus but delayed by up to two days to control omicron-era severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Furthermore, while rapid tests are superior to reverse transcription quantitative polymerase chain reaction (RT-qPCR) to control founder-strain SARS-CoV-2, omicron-era changes in viral kinetics and rapid test sensitivity cause a reversal, with higher TE for RT-qPCR despite longer turnaround times. Last, we illustrate the model’s flexibility by quantifying trade-offs in the use of post-diagnosis testing to shorten isolation times.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2HumansCOVID-19 TestingCommunicable DiseasesInfluenza, HumanRespiratory Syncytial Virus InfectionsModels, Theoretical

Autor:innen und Institutionen

  • Department of Computer Science, University of Colorado Boulder, Boulder, CO, USA.
  • BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USA.
  • Santa Fe Institute, Santa Fe, NM, USA.

ORCID-Profile: Casey Middleton, Daniel B Larremore

Förderung

  • NCI NIH HHS

Zitieren

APA

Middleton, C., & Larremore, D. B. (2024). Modeling the transmission mitigation impact of testing for infectious diseases. Science Advances. https://doi.org/10.1126/sciadv.adk5108

Vancouver

Middleton C, Larremore DB. Modeling the transmission mitigation impact of testing for infectious diseases. Science Advances. 2024. doi:10.1126/sciadv.adk5108

BibTeX
@article{Middleton2024,
  author = {Middleton, Casey and Larremore, Daniel B},
  title = {Modeling the transmission mitigation impact of testing for infectious diseases},
  journal = {Science Advances},
  year = {2024},
  doi = {10.1126/sciadv.adk5108}
}
Kostenlos starten →